Rhythm Pharmaceuticals, Inc. (RYTM)Healthcare | Biotechnology | Boston, United States | NasdaqGM
87.97 USD
+1.26
(1.453%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 87.97 |
Hot Take ↕ | Oct. 10, 2026, 10:20 a.m. EDT
The long-term investment case remains compelling despite recent technical weakness. Over the past eight years, the stock has delivered a cumulative gain of nearly 288%, reflecting a powerful multi-year upward trajectory that validates the underlying business quality. Revenue growth is robust at 47%, and gross margins are healthy, though the company is still burning cash, which prevents a top-tier rating. The balance sheet is fortified with low debt and strong liquidity, providing a safety net for continued R&D investment. In the short term, the chart is under pressure, trading below both the 50-day and 200-day moving averages after a sharp two-week decline. This technical breakdown creates a cautious outlook for the immediate future, even as options flow suggests traders are buying insurance against a crash while betting on a rebound. The divergence between the weak price momentum and the bullish options positioning indicates a period of uncertainty ahead of the next major catalyst. Investors should view the current dip as a potential entry point for a long-term hold, rather than a signal to exit, given the substantial analyst upside targets and the company's dominant position in its therapeutic niche. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.046598 |
| AutoETS | 0.048169 |
| AutoARIMA | 0.048170 |
| AutoTheta | 0.076065 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 1.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.291 |
| Excess Kurtosis | -1.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 50.522 |
| Revenue per Share | 3.557 |
| Market Cap | 6,034,177,024 |
| Forward P/E | -138.83 |
| Beta | 2.01 |
| Profit Margins | -85.59% |
| Website | https://rhythmtx.com |
As of Oct. 10, 2026, 10:20 a.m. EDT: Speculators are positioning for significant upside potential, evidenced by heavy out-of-the-money call open interest at strikes above the current price (115, 120, 155). Implied volatility remains elevated on near-term calls, suggesting anticipation of a catalyst-driven move. While put open interest exists for downside protection, the call skew indicates a bullish sentiment among traders expecting a recovery or breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.22009355 |
| Address1 | 222 Berkeley Street |
| Address2 | 12th Floor |
| All Time High | 122.2 |
| All Time Low | 3.04 |
| Ask | 140.85 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 848,610 |
| Average Daily Volume3 Month | 672,464 |
| Average Volume | 672,464 |
| Average Volume10Days | 848,610 |
| Beta | 2.009 |
| Bid | 77.4 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.496 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 87.97 |
| Current Ratio | 3.452 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 90.36 |
| Day Low | 87.61 |
| Debt To Equity | 50.522 |
| Display Name | Rhythm Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,844,800 |
| Earnings Call Timestamp Start | 1,785,844,800 |
| Earnings Timestamp | 1,785,846,600 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | -199,550,000 |
| Ebitda Margins | -0.83174 |
| Enterprise To Ebitda | -29.818 |
| Enterprise To Revenue | 24.801 |
| Enterprise Value | 5,950,122,496 |
| Eps Current Year | -3.06107 |
| Eps Forward | -0.63364 |
| Eps Trailing Twelve Months | -3.16 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 857 264 4299 |
| Fifty Day Average | 102.9894 |
| Fifty Day Average Change | -15.019402 |
| Fifty Day Average Change Percent | -0.14583443 |
| Fifty Two Week Change Percent | -22.009356 |
| Fifty Two Week High | 122.2 |
| Fifty Two Week High Change | -34.229996 |
| Fifty Two Week High Change Percent | -0.28011453 |
| Fifty Two Week Low | 74.5 |
| Fifty Two Week Low Change | 13.470001 |
| Fifty Two Week Low Change Percent | 0.18080539 |
| Fifty Two Week Range | 74.5 - 122.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,507,555,800,000 |
| Float Shares | 56,037,332 |
| Forward Eps | -0.63364 |
| Forward P E | -138.83278 |
| Free Cashflow | -130,588,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 414 |
| Fullday Change | 1.2600021 |
| Fullday Change Percent | 1.453122 |
| Fullday Price | 87.97 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.89001 |
| Gross Profits | 213,528,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0069999998 |
| Held Percent Institutions | 1.15113 |
| Implied Shares Outstanding | 68,593,574 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. |
| Long Name | Rhythm Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 6,034,177,024 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_309184792 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -210,222,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,764,028,535 |
| Number Of Analyst Opinions | 17 |
| Open | 88.41 |
| Operating Cashflow | -105,348,000 |
| Operating Margins | -0.68138003 |
| Overall Risk | 9 |
| Phone | 857 264 4280 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 87.97 |
| Post Market Time | 1,792,100,230 |
| Previous Close | 86.71 |
| Price Eps Current Year | -28.738317 |
| Price Hint | 2 |
| Price To Book | 58.803474 |
| Price To Sales Trailing12 Months | 25.150997 |
| Profit Margins | -0.8559 |
| Quick Ratio | 3.004 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 1.26 |
| Regular Market Change Percent | 1.45312 |
| Regular Market Day High | 90.36 |
| Regular Market Day Low | 87.61 |
| Regular Market Day Range | 87.61 - 90.36 |
| Regular Market Open | 88.41 |
| Regular Market Previous Close | 86.71 |
| Regular Market Price | 87.97 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 547,683 |
| Return On Assets | -0.30961 |
| Return On Equity | -1.17045 |
| Revenue Growth | 0.469 |
| Revenue Per Share | 3.557 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 68,593,574 |
| Shares Percent Shares Out | 0.15640001 |
| Shares Short | 10,767,698 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,303,031 |
| Short Name | Rhythm Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1576 |
| Short Ratio | 16.33 |
| Source Interval | 15 |
| State | MA |
| Symbol | RYTM |
| Target High Price | 160.0 |
| Target Low Price | 120.0 |
| Target Mean Price | 140.29411 |
| Target Median Price | 143.0 |
| Total Cash | 330,896,992 |
| Total Cash Per Share | 4.806 |
| Total Debt | 109,784,000 |
| Total Revenue | 239,918,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.16 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 97.98365 |
| Two Hundred Day Average Change | -10.013649 |
| Two Hundred Day Average Change Percent | -0.10219714 |
| Type Disp | Equity |
| Volume | 547,683 |
| Website | https://rhythmtx.com |
| Zip | 2,116 |